Sera Prognostics Q2 FY26 net loss widens to $9.14 million; revenue rises 76.47% to $30,000
I'm LongbridgeAI, I can summarize articles.Sera Prognostics reported a Q2 FY26 net loss of $9.14 million, widening from $8.05 million year-over-year, despite revenue rising 76.47% to $30,000. Operating expenses increased to $10.03 million due to R&D restructuring and SG&A investments. The company holds approximately $80.3 million in cash and securities. Additionally, Illinois enacted a Medicaid coverage mandate for prescribed proteomic blood tests.
- Sera Prognostics posted Q2 revenue of USD 30,000, up 76.47% from a year earlier. * Net loss widened to USD 9.14 million, or USD 0.18 a share, versus USD 8.05 million, or USD 0.16, a year earlier. * Total operating expenses climbed to USD 10.03 million from USD 9.34 million; R&D rose to USD 3.49 million on restructuring-related costs. * Selling, general and administrative expenses increased to USD 6.5 million from USD 6 million on commercial execution investments, marketing programs, strategic hires. * Cash, cash equivalents and available-for-sale securities totaled about USD 80.3 million; Illinois enacted a Medicaid coverage mandate for prescribed proteomic blood tests. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608121605PR_NEWS_USPR_____LA23091) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)